Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) was the recipient of unusually large options trading on Thursday. Stock traders bought 12,612 call options on the company. This represents an increase of approximately 235% compared to the typical daily volume of 3,762 call options.

Wall Street Analyst Weigh In

Several research firms have commented on OMER. HC Wainwright reissued a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. Finally, Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Omeros Stock Up 23.2%

Shares of OMER stock traded up $3.19 during trading hours on Thursday, reaching $16.90. 6,079,697 shares of the company’s stock were exchanged, compared to its average volume of 1,637,689. Omeros has a fifty-two week low of $3.94 and a fifty-two week high of $18.14. The stock has a market capitalization of $1.22 billion, a P/E ratio of 24.12 and a beta of 2.54. The business has a fifty day moving average price of $10.60 and a 200-day moving average price of $11.47.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, research analysts expect that Omeros will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Thomas J. Cable sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the transaction, the director owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.50% of the company’s stock.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the stock. International Assets Investment Management LLC raised its stake in shares of Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 800 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Omeros by 16.5% during the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,004 shares in the last quarter. State of Wyoming bought a new stake in Omeros in the fourth quarter valued at about $25,000. AQR Capital Management LLC increased its stake in Omeros by 7.2% in the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,532 shares during the period. Finally, ProShare Advisors LLC increased its stake in Omeros by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 1,637 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros News Summary

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Significant earnings and revenue beats: Omeros reported second-quarter earnings of $0.02 per share, versus analysts’ expected loss of $0.27 per share and a $0.53 loss a year earlier. Revenue reached $28.53 million, more than double the $12.69 million consensus estimate. The results improved investor confidence in the company’s commercial performance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: YARTEMLEA momentum is supporting the outlook: Management highlighted strong early demand for YARTEMLEA, which is becoming an important commercial growth driver. Analysts also cited reduced competition in the C5 market as a positive factor for the product’s potential. Omeros Earnings Call: Yartemlia Surge and Leaner Balance Sheet
• Positive Sentiment: Balance-sheet and shareholder actions added to the catalyst: The earnings update emphasized debt reduction and a leaner balance sheet, while share repurchases provided an additional potential source of per-share support. OMER Stock Soars After YARTEMLEA Sales Momentum, Debt Reduction and Share Buybacks
• Positive Sentiment: Analyst remains bullish: H.C. Wainwright reiterated its Buy rating and maintained a $33 price target, citing YARTEMLEA’s launch trajectory and reduced C5 competition. This target is well above the stock’s recent trading range and reinforces the bullish reaction to the results. Omeros Maintained at Buy With $33 Price Target
• Neutral Sentiment: Reported short-interest data showed zero shares sold short, offering no meaningful short-squeeze or bearish-positioning signal.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.